-
2019-nCoV spike protein RBD (L452R, E484Q)
2019-nCoV spike protein RBD (L452R, E484Q)
- 中文名称：
- 2019-nCoV spike protein RBD (L452R, E484Q)
- 英文名称：
- 2019-nCoV spike protein RBD (L452R, E484Q)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA73337
- 规格：
- 0.01 mg|0.02 mg|0.05 mg|0.1 mg|2x0.1 mg
- 保存建议：
- Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
- 货期：
- 6-8周
- 纯度：
- N/A
- 产品形式：
- Recombinant protein stored in 50mM sodium phosphate, pH7.5, 300mM NaCl, 150mM imidazole.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Recombinant 2019-nCoV Spike protein S1 subunit, RBD (L452R, E484Q)(319-541) was expressed in CHO cells using a C-terminal his tag. The gene accession number is MN908947.
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein that recognizes the host ACE2 receptor is a major determinant of viral entry and neutralization, and is the most divergent region (1). Lineage B.1.617, also known as the Indian variant carries unique combination of E484Q and L452R mutations in the RBD of the spike protein. L452R mutation has been previously reported in the California variant (B1.429). Mutation at E484 have been detected in the South African (B.1.351), Brazilian (P.1), and NY variants (B.1.526). Viruses harboring these individual mutations have reduced susceptibility to both monoclonal antibodies and convalescent plasma (2). As these new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).
